Revenue recognition - Percentage of Product Sales (Details) - Sales Revenue, Product Line - Product Concentration Risk	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Anthrax vaccines
Concentration Risk [Line Items]
Concentration risk percentage	28.00%	25.00%	38.00%
Nasal naloxone products
Concentration Risk [Line Items]
Concentration risk percentage	39.00%	43.00%	31.00%
TEMBEXA
Concentration Risk [Line Items]
Concentration risk percentage	12.00%	0.00%	0.00%
ACAM2000
Concentration Risk [Line Items]
Concentration risk percentage	7.00%	20.00%	20.00%
Other products
Concentration Risk [Line Items]
Concentration risk percentage	14.00%	12.00%	11.00%